UCLA advances CRISPR gene-editing therapy for sickle cell disease
A UCLA-led team has described how they advanced an experimental CRISPR approach for sickle cell disease into a blood stem cell therapy that can be manufactured at the scale and quality required for a clinical trial.
Read original article on The Medical News →Related news
-
Brain scans reveal clues to Alzheimer's risk years before memory loss begins
United Kingdom
-
Three-drug combination remodels immune environment in gastric cancer
United Kingdom
-
Simple text reminders could help close London's bowel cancer screening gap
United Kingdom
-
Teen chlamydia and gonorrhea screening climbs to 75% after primary care changes
United Kingdom
-
Targeting brain protein may help treat MEF2C-related neurological disorders
United Kingdom
-
ACS Emergency General Surgery Verification associated with fewer deaths and shorter stays
United Kingdom
-
Knee osteoarthritis: Symptoms, diagnosis and treatment
United Kingdom
-
Workplace exposure to petroleum-based lubricants linked to higher MS risk
United Kingdom